Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : QEL-001
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : eXmoor pharma
Deal Size : Undisclosed
Deal Type : Partnership
Quell Therapeutics Expands CAR-Treg Manufacturing with eXmoor Pharma
Details : Quell & eXmoor are partnering on the process transfer, scale-up, and Phase 1/2 clinical manufacturing of multiple autologous CAR-Treg cell therapies, including QEL-001, for liver transplant patients.
Brand Name : QEL-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 24, 2024
Lead Product(s) : QEL-001
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : eXmoor pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : QEL-001
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Quell's QEL-001 CAR-Treg Therapy Moves to Phase 1/2 Trial for Liver Transplant Patients
Details : QEL-001, its autologous engineered CAR-Treg cell therapy, which is being investigated in Phase 1/2 trial in patients with liver transplant patients.
Brand Name : QEL-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 04, 2024
Lead Product(s) : QEL-001
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Treg-based Cell Therapy
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : AstraZeneca
Deal Size : $2,085.0 million
Deal Type : Collaboration
Details : The collaboration aims to focus on the type 1 diabetes and inflammatory bowel disease using Quell’s proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock, to develop autologous multi-modular Treg cell thera...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : $85.0 million
June 09, 2023
Lead Product(s) : Treg-based Cell Therapy
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : AstraZeneca
Deal Size : $2,085.0 million
Deal Type : Collaboration
Lead Product(s) : QEL-001
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Jeito Capital
Deal Size : $156.0 million
Deal Type : Series B Financing
Details : Proceeds to be used to fund clinical development of QEL-001 in liver transplantation, to accelerate development of its product pipeline across transplantation, neuroinflammatory and autoimmune diseases, and enhance its multi-modular engineered Treg platf...
Brand Name : QEL-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 29, 2021
Lead Product(s) : QEL-001
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Jeito Capital
Deal Size : $156.0 million
Deal Type : Series B Financing
Lead Product(s) : Multi-modular Engineered Treg Cell Therapy
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The QEL-001 CAR is specific for HLA-A2, which localizes the activity of the CAR-Tregs to the site of the transplanted organ in HLA-A2 mismatch liver transplant patients (i.e. HLA-A2 negative recipients who received an HLA-A2 positive donor liver).
Brand Name : QEL-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 27, 2021
Lead Product(s) : Multi-modular Engineered Treg Cell Therapy
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?